The aim of this study was to assess the long-term impact of high-dose chemotherapy (HDC) as consolidation in a large series (n = 55) of advanced chemosensitive ovarian cancer patients who were optimally cytoreduced at time of first surgery or at interval debulking surgery (IDS). 
It has been demonstrated that patients with platinumsensitive disease and minimal tumor burden at the time of HDC experience a survival advantage compared with patients bearing platinum-resistant, bulky disease. 1, 3, [5] [6] [7] These observations encouraged the use of HDC early in treatment, hopefully maximizing efficacy in patients with minimal chemosensitive disease.
Limited data are available on HDC with progenitor cell support as first-line treatment in advanced ovarian cancer, and the ideal patient population and treatment regimen for this approach have yet to be defined. 1, [7] [8] [9] [10] [11] [12] Our previous report on HDC in ovarian cancer showed encouraging results in terms of prolongation of time to progression and overall survival 12 and acceleration of hematopoietic recovery due to the combined administration of PBSC and growth factors. 13 Here, we report the updated results of the use of HDC 12 in a larger series of patients. The long-term impact of HDC has been investigated in patients selected on the basis of pathological characteristics and the presence of chemosensitive disease.
Patients and methods
The study was undertaken in a single institution during an 8-year period (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) and included 55 consecutive patients with advanced ovarian carcinoma.
As previously described, 12, 13 eligibility criteria for HDC were the presence of histologically confirmed, advanced (FIGO stage IIIB-IV) epithelial ovarian cancer with a residual tumor р2 cm achieved at primary cytoreductive surgery or interval debulking surgery (IDS), no signs of progression after induction chemotherapy, age younger than 60 years, performance status of 0-1 (WHO scale), adequate bone marrow reserve (WBC count Ͼ4000 ϫ 10 6 /l, platelet count Ͼ100 ϫ 10 9 /l) and adequate pulmonary, cardiac, hepatic and renal function, as previously described. 12, 13 The study was approved by the Hospital Human Investigation Review Board of the Catholic University and all patients gave informed consent.
Clinical and pathological characteristics of patients are detailed in Table 1 . Most of the patients (47/55; 85%) had advanced disease at primary surgery (FIGO stage IIIC-IV) and 18 (33%) required additional surgery (intestinal resection, diaphragm stripping) to achieve optimal cytoreduction. Figure 1 shows a flow chart of the original patient population, detailing the distinct phases of the study. The vast majority of the patients received PBSC while the first four patients received ABMT. The four patients receiving ABMT were optimally cytoreduced at first surgery and all had serous, poorly differentiated, stage IIIC disease, with ages ranging from 44 to 53 years. All of them had been allocated to treatment plan A. As previously reported, 12 the first 20 patients did not receive hematopoietic growth factors after ABMT/PBSC reinfusion. Combinations of recombinant human erythropoietin (rh-EPO; Globuren, Dompe' Biotec, Milan, Italy), recombinant human granulocyte colony-stimulating factor (rh-G-CSF; Neupogen, Dompe' Biotec), and recombinant human granulocyte-macrophage colony-stimulating factor (rh-GM-CSF; Mielogen Schering Plough, Milan, Italy), were administered to the remaining 35 patients after PBSC reinfusion.
Treatment plan and supportive care
The treatment plan for the previously reported series of 20 patients (treatment plan A) has been described elsewhere, 12 and is summarized in Table 2 . Table 3 describes the treatment plan adopted in the latest series of patients (treatment plan B). Briefly, the induction , days 3 and 4). PBSC were re-infused on day 5. Twenty-four hours later, patients received rh-EPO at a dose of 150 IU/kg s.c. every 48 h until day +11, plus 5 g/day rh-G-CSF s.c. until day +12 (17 cases), or rh-GM-CSF (5 g/kg) every 24 h s.c. until day +12 (10 cases), or both rh-G-CSF and rh-GM-CSF as above (eight cases). All patients were nursed in conventional single-bed rooms, and access to patients' rooms required masks, gloves, gowns, and shoe covers. Patients received parenteral hyperalimentation from the time of HDC until complete hemopoietic recovery. Antimicrobial and antifungal prophylaxis consisted of the daily administration of ciprofloxacin (1000 mg/day), fluconazole (150 mg/day), acyclovir (800 mg/day) and trimethoprim/sulphamethoxazole (960 mg/day) twice a week from intensification to day +40. During neutropenia, empiric antibiotic therapy was administered when fever exceeded 38°C for more than 12 h and amphotericin B was added if fever persisted for more than 7 days in spite of antibiotic treatment. Irradiated red blood cells (RBC) and single donor platelets were transfused to maintain Hb count Ͼ8.5 g/dl and platelet count Ͼ10 ϫ 10 9 /l. Hematopoietic engraftment was defined as the number of days necessary to reach white blood cells (WBC) Ͼ1 ϫ 10 9 /l, polymorphonuclear leukocytes (PMN) Ͼ0.5 ϫ 10 9 /l and platelets Ͼ50 ϫ 10 9 /l. All patients were discharged from the hospital when their PMN and platelet counts reached a value of 1 ϫ 10 9 /l and 50 ϫ 10 9 /l, respectively, in the absence of fever or infectious episodes. Non-hematologic toxicities were graded using the standard World Health Organization (WHO) system.
Definition and assessment of response
Clinical and pathological responses were defined according to the WHO criteria. 15 Two to 4 months after HDC, patients in clinical complete remission underwent a laparoscopic/ laparotomic assessment of response. Multiple biopsies and peritoneal cytology were required to assess pathological response. Bone Marrow Transplantation the date of death or clinical/pathological progression. All medians and life tables were computed using the productlimit estimates by Kaplan and Meier. 16 The median follow up was 55 months (range 17-137). Analysis was carried out in September 2000.
Statistical analysis

Results
Response and survival
Fifty-five patients received HDC and 53 were evaluable for response and survival since two died of transplant-related complications.
In the overall population a pathologically documented complete response was observed in 34/53 (64%) (CI 95%: 51-77). Nine of these 34 patients (26.5%) had been allocated to treatment plan A and 25 (73.5%) to treatment plan B. We detected a microscopic partial response in 9/53 (Table 4) . When response to HDC was examined according to feasibility of cytoreduction at first surgery, a complete response was observed in 74% (CI 95%: 59-88) of patients optimally cytoreduced at primary surgery and in 44% (CI 95%: 21-66) of patients cytoreduced at the time of IDS. During follow-up there were 38 recurrences and 28 disease-related deaths. Most recurrences were only abdominal (n = 19, 50%), only hepatic (n = 5, 13%), or simultaneously abdominal and hepatic (n = 11, 29%). Simultaneous involvement of abdomen and retroperitoneum was observed in two cases (5%), while retroperitoneum was the only site of recurrence in one case (2.5%).
The 5-year OS was 60% (CI 95%: 38-83) (median OS: 75 months) in patients who received treatment plan A, whereas patients on treatment plan B had a 5-year OS of 58% (CI 95%: 41-75) (median OS: 75 months) (P value NS). Similarly, TTP curves did not differ according to treat- Table 4 Response to VHDC ment plan. Figure 2 shows TTP and OS curves in the overall population (a, b), in patients with optimal primary cytoreduction (c, d) and in those optimally cytoreduced at the time of IDS (e, f).
In the overall population the median TTP was 35 months with a 5-year TTP of 35% (CI 95%: 21-49). Median OS was 75 months with a 5-year OS of 59% (CI 95%: 45-73) (Figure 2a, b) . Patients optimally cytoreduced at the time of primary surgery had a median TTP of 44 months with a 5-year rate of 43% (CI 95%: 26-60) (Figure 2c ). In the same subgroup, the 5-year OS rate was 62% (CI 95%: 45-79) (median OS = 75 months) (Figure 2d ). In patients who were optimally cytoreduced at time of IDS the median TTP was 25 months and the 5-year TTP rate was 22% (CI 95% 3-41) (Figure 2e ). The median OS was 46 months with a 5-year OS rate of 50% (CI 95%: 27-73) (Figure 2f ). The 5-year TTP rate was 50% (CI 95%: 32-68) (median TTP 57 months) and the OS at 5 years 70% (CI 95%: 54-86) (median 107) for patients who achieved a complete pathological response (data not shown). Finally, analysis of the therapeutic impact of second-line chemotherapy in patients who had a disease recurrence after HDC (12 patients relapsed after 12 months and received platinum-based chemotherapy while six had relapse within 12 months and were treated by taxol-or topotecan-based regimens) indicate that only three out of 18 (16.6%) patients responded to second-line treatment. Non-hematological toxicity: Two treatment-related deaths (3.6%) occurred in a 51-year-old (this patient received ABMT) and a 42-year old patient who developed candida sepsis and malignant hyperthermia, respectively. Data relative to non-hematological toxicity are detailed in Table 5 . Mild to moderate enteritis (grade I and II) was observed in 44/55 patients (80%), while only 3/55 patients (5%) had grade III. Most patients (91%, 50 patients) experienced grade I/II nausea and vomiting but only 9% (five patients) had grade III. An increase in liver enzymes was observed in most patients (95%) but only 14% (eight patients) had grade IV. Mucositis was observed in only 45% (25 patients) of the patients. Mild renal toxicity (consisting of grade I proteinuria) was observed in 29% (16 patients) of the patients. Only 10 patients (18%) experienced mild Table 5 Non-hematological toxicity a (18) Cardiac toxicity 55 (100) Neural toxicity 11 (20) 36 (65) 6 (10) 2 (4) Renal toxicity 36 (65) 16 (29) 3 (5) a Non-hematological toxicity was evaluated according to the WHO scale. There were 55 patients evaluable.
Toxic effects Grade 0 (%) 1 (%) 2 (%) 3 (%) 4 (%)
hemorrhagic cystitis with grade I hematuria. None of the patients experienced any cardiac toxicity. No late or long lasting effects have been noted to date.
Hematological toxicity: Severe myelosuppression occurred in all patients (Table 6) . Patients who received rh-G-CSF + rh-EPO (group B) recovered significantly earlier from leukopenia and neutropenia than did the other groups. In particular, a PMN count Ͼ0.5 ϫ 10 9 /l and a WBC count Ͼ1 ϫ 10 9 /l occurred significantly earlier in group B than in groups A (no growth factors) and C (rh-GM-CSF + rh-EPO). Patients in group D (rh-G-CSF + rh-GM-CSF + rh-EPO) had a WBC and PMN recovery comparable to that observed in group B. The number of days with a PMN count Ͻ0.2 ϫ 10 9 /l and Ͻ0.5 ϫ 10 9 /l was significantly lower in group B as compared to group A (P = 0.005), while no significant difference was observed between groups B, C and D (Table 6 ). Conversely, the number of days with a WBC count Ͻ1 ϫ 10 9 /l was significantly lower for groups B (P = 0.009) and C (P = 0.045) as compared to group A ( Table 3 ). The administration of rh-G-CSF + rh-GM-CSF + rh-EPO did not result in a statistically significant reduction in the number of days with a WBC count Ͻ1 ϫ 10 9 /l when compared to group A (P = 0.30). Patients in group B required a lower number of single-donor platelet transfusions as compared to group D (P = 0.007) and A (borderline significance). Most patients did not require RBC transfusions.
Fever and infection
Seventy-five per cent of the patients in group A, 85% in group C, and 80% in group D developed fever while none of the patients in group B experienced fever episodes. A microbiologically documented infection occurred in only one patient in group A (Candida glabrata). Fever episodes required systemic antibiotic treatment in all patients in group A, while the sporadic occurrence of febrile episodes in group C and D discouraged the use of systemic antiobiotics. Consequently, in groups B, C and D systemic antibiotics were not administered to any patient (Table 6 ).
Hospital stay
Group B and C patients were discharged from hospital after a shorter period of time than group A patients ( Table 6 ). The mean ± s.d. hospital stay (including the period required for CEM administration) was 22.3 ± 6.4 days for group A, 18.2 ± 2.0 days for group B, 16.5 ± 2.5 days for group C and 18.6 ± 1.1 days for group D.
Discussion
This study follows a previously reported pilot trial 12 and was aimed at evaluating the long-term impact of the HDC approach on TTP and OS in advanced ovarian cancer patients. Patients were enrolled in the HDC strategy on the basis of tumor characteristics such as chemosensitivity and minimal tumor burden, which have been shown to be good predictors of response to HDC. 3, 6 In our study, similar to the data reported by Legros et al, 8 no difference in outcome of patients receiving different HDC regimens has been observed suggesting that, once a threshold dose is achieved, the relevance of administering drugs with different mechanisms of action is not so critical. In the whole series of patients we observed 59% and 35% 5-year OS and TTP rates, respectively, which seem quite comparable to results reported by other authors 8, 17 in smaller series of ovarian cancer patients who received HDC as late consolidation. Given the unfavorable characteristics of our patient population (85% stage IIIc-IV; 78% G2-G3 tumors) our data seem encouraging as compared to the 5-year OS rate of 25-35% observed after standard chemotherapy regimens in patients with similar characteristics. [18] [19] [20] [21] [22] [23] On the other hand, a comparison of our data with the results of standard-dose cisplatin-based chemotherapy remains difficult to interpret due to the fact that most patients in our series were enrolled in the HDC program in chemosensitive status. 24 Interestingly, we observed that in patients inoperable at first surgery (these patients underwent succesful IDS) and therefore endowed with a poor prognosis 25,26 the 5-year OS rate (54%) and the median OS (75 months) seem to be higher than those (5-year OS ranging from 22% to 35% with a median OS of 25 months) seen with standard chemotherapy. 25, 26 Available data on HDC in patients cytoreduced at the time of IDS are scanty and mostly uninterpretable; 3, 8, 17 nevertheless, our data are in good keeping with the results reported by Legros et al, 8 and suggest that ovarian cancer patients with inoperable disease at diagnosis may still benefit from HDC if tumors are chemosensitive and optimal debulking can be performed by IDS. In this patient subset the extent of benefit seems even greater than in patients optimally cytoreduced at first surgery, although the very wide range of confidence intervals does not allow any definitive conclusions to be drawn. This apparent discrepancy could be explained by more stringent selection of chemosensitive cases in the IDS subgroup than in patients optimally debulked at first surgery. This latter group probably included a good percentage of patients in whom radical surgery made their enrollment in the HDC program possible in the absence of a true chemosensitive status.
In our series HDC produced an improvement in overall survival without resulting in a substantial benefit in terms of TTP, as might be expected considering that HDC should Bone Marrow Transplantation be able to effect a better tumor control, delaying the regrowth of residual clones. Moreover, in our series (at variance with the results reported by Legros et al 8 HDC negatively influenced subsequent likelihood of responding to platinum re-challenge or to other drugs. From these data, we can hypothesize that the improvement in overall survival produced by HDC could be due to post-HDC modifications of cancer cell and/or host cell biology which render the behaviour of residual disease more indolent. With reference to this, modifications of immunologic functions, such as amplification of LAK activity during the post-HDC immuno-hematopoietic reconstitution, have been demonstrated. 27 Hence, a more in-depth definition of tumor and host biological characteristics during HDC could be of major interest.
HDC with PBSC reinfusion and growth factor administration was shown to be a reasonably manageable procedure. Non-hematological toxicity was comparable to or even better with respect to previously reported studies using similar combinations of cytotoxic drugs. Moreover, the percentage of therapy-related deaths was in keeping with the results reported in the literature. 3, 8, 10 The clinical benefits produced by the use of hematopo-ietic growth factors after HDC and PBSC reinfusion are well established 13, 28 even though the ideal combinations of growth factors have yet to be defined. We reported previously the advantage of adding rh-EPO to myelopoietic growth factors which translates into a potentiation of their effects in vitro and in vivo. 29, 30 In the present study, we demonstrated that the combination of three growth factors did not yield any improvement in hematologic recovery or in the clinical management of patients with respect to the use of rh-G-CSF plus rh-EPO or rh-GM-CSF plus rh-EPO. Instead, patients who received the three factors experienced a longer period of fever, and required a higher number of red blood cell and platelet transfusions as compared to the groups receiving only two factors. It is conceivable that the combined use of rh-GM-CSF plus rh-G-CSF could force progenitor commitment toward the myeloid lineage, removing progenitors from other hematopoietic lineages through a mechanism of in vivo progenitor competition. On the other hand, our observation that the serum levels of endogenous thrombopoietin, which has been reported to promote platelet rescue, 31 are significantly decreased in patients treated with three factors as compared with patients who received two cytokines or no factors at all is of interest (manuscript submitted).
In conclusion, our observations suggest that HDC with hematopoietic support could represent an effective doseintensified approach for the treatment of advanced, optimally cytoreduced chemosensitive ovarian cancer. Moreover, HDC produced a survival benefit in advanced ovarian cancer considered unresectable at the time of first surgery probably because of a more reliable selection of chemosensitive cases.
In the near future a more in-depth characterization of tumor chemosensitivity from a biological point of view could improve the selection of patients who can really benefit from HDC. Finally, randomized phase III studies should define the role of HDC in treatment of advanced ovarian cancer.
